Related Experiment Video
Updated: Dec 9, 2025

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
Transient Receptor Potential Ankyrin Type-1 Channels as a Potential Target for the Treatment of Cardiovascular
Song Gao1, Keneilwe Kenny Kaudimba1, Shanshan Guo1
1School of Kinesiology, Shanghai University of Sport, Shanghai, China.
Insights
Transient Receptor Potential Ankyrin 1 (TRPA1) channels in the vascular endothelium show complex roles in cardiovascular diseases. Understanding TRPA1
Area of Science:
- Cardiovascular physiology and pharmacology
- Ion channel biology
- Endothelial function
Background:
- Cardiovascular diseases (CVDs) are a leading global cause of mortality.
- Hypertension, metabolic disorders, and smoking are key risk factors for CVDs.
- Targeting novel pathways is crucial for effective CVD drug development.
Purpose of the Study:
- To review the structural and functional characteristics of Transient Receptor Potential Ankyrin 1 (TRPA1).
- To explore the role of TRPA1 in vascular physiology and its association with cardiovascular diseases.
- To summarize evidence linking TRPA1 to CVD risk factors.
Main Methods:
- Literature review of existing studies on TRPA1.
- Analysis of TRPA1 expression in vascular endothelium.
- Synthesis of data on TRPA1's role in atherosclerosis, myocardial fibrosis, heart failure, and arrhythmia.
Main Results:
- TRPA1 channels are expressed in the vascular endothelium, a key player in CVDs.
- TRPA1 activation has beneficial effects on atherosclerosis.
- TRPA1 activation negatively impacts myocardial fibrosis and heart failure.
Conclusions:
- TRPA1 presents a complex, context-dependent role in cardiovascular pathophysiology.
- TRPA1 is a potential therapeutic target for cardiovascular diseases, with differential effects.
- Further research into TRPA1 modulation could yield novel CVD treatments.
Abstract:
Cardiovascular disease is one of the chronic conditions with the highest mortality rate in the world. Underlying conditions such as hypertension, metabolic disorders, and habits like smoking are contributors to the manifestation of cardiovascular diseases. The treatment of cardiovascular diseases is inseparable from the development of drugs. Consequently, this has led to many researchers to focus on the search for effective drug targets. The transient receptor potential channel Ankyrin 1 (TRPA1) subtype is a non-selective cation channel, which belongs to the transient receptor potential (TRP) ion channel. Previous studies have shown that members of the TRP family contribute significantly to cardiovascular disease. However, many researchers have not explored the role of TRPA1 as a potential target for the treatment of cardiovascular diseases. Furthermore, recent studies revealed that TRPA1 is commonly expressed in the vascular endothelium. The endothelium is linked to the causes of some cardiovascular diseases, such as atherosclerosis, myocardial fibrosis, heart failure, and arrhythmia. The activation of TRPA1 has a positive effect on atherosclerosis, but it has a negative effect on other cardiovascular diseases such as myocardial fibrosis and heart failure. This review introduces the structural and functional characteristics of TRPA1 and its importance on vascular physiology and common cardiovascular diseases. Moreover, this review summarizes some evidence that TRPA1 is correlated to cardiovascular disease risk factors.
More Related Videos
Related Concept Videos
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
G-Protein Gated Ion Channels
Sensory...
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Ligand-Gated Ion Channel Receptor: Gating Mechanism

